Volume 94 Issue 39 | p. 17 | Concentrates
Issue Date: October 3, 2016

Amgen licenses RNAi drugs from Arrowhead

Department: Business
Keywords: drug delivery, RNAi, cardiovascular disease

Amgen has licensed RNAi drug and subcutaneous drug delivery technology from Arrowhead Pharmaceuticals for cardiovascular disease. The big biotech firm will pay Arrowhead $35 million up front, $22 million in an equity investment, and up to $617 million in option and milestone payments. The deal includes Arrowhead’s RNAi ARC-LPA program, which brings molecules designed to reduce elevated lipoprotein(a), a risk factor for heart disease.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment